Education
About Us
Working with TipRanks
Follow Us
Novo Nordisk (DE:NOVA)
FRANKFURT:NOVA
NOVA Stock Chart & Stats
Day’s Range― - ―
52-Week Range€38.20 - €126.00
Previous CloseN/A
Volume1.40K
Average Volume (3M)5.39K
Market Cap
$190.65B
Enterprise Value€319.55B
Total Cash (Recent Filing)$18.93B
Total Debt (Recent Filing)$99.27B
Price to Earnings (P/E)12.7
Beta0.65
Next Earnings
Nov 05, 2025EPS Estimate
0.82Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.80
Shares Outstanding3,390,128,000
10 Day Avg. Volume10,831
30 Day Avg. Volume5,387
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.68
Enterprise Value/Revenue1.02
Enterprise Value/Gross Profit1.22
Enterprise Value/Ebitda1.87
Forecast
1Y Price Target
$56.49Price Target Upside29.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Leadership ChangeA new CEO, Mike Doustdar, has been appointed, potentially bringing a global perspective and re-energizing the struggling strategy.
Pipeline InnovationNovo Nordisk is committed to driving the next wave of pipeline innovation.
Product DevelopmentNovo Nordisk is pushing ahead with high-dose oral semaglutide for the treatment of obesity as an option for patients who may not want to use injectables.
Bears Say
Competitive PressureOzempic's US underperformance is accentuated by competition in the US, leading to weaker-than-expected sales.
Market CompetitivenessNovo Nordisk shares are expected to remain less competitive versus other peers in the cardiometabolic market.
Sales PerformanceLower Wegovy sales expectations were specifically impacted by continued/higher-than-expected compounding in the US market and slower-than-expected market expansion.
Novo Nordisk News
NOVA FAQ
What was Novo Nordisk’s price range in the past 12 months?
Novo Nordisk lowest stock price was €38.20 and its highest was €126.00 in the past 12 months.
What is Novo Nordisk’s market cap?
Novo Nordisk’s market cap is $190.65B.
When is Novo Nordisk’s upcoming earnings report date?
Novo Nordisk’s upcoming earnings report date is Nov 05, 2025 which is in 82 days.
How were Novo Nordisk’s earnings last quarter?
Novo Nordisk released its earnings results on Aug 06, 2025. The company reported €0.797 earnings per share for the quarter, beating the consensus estimate of €0.79 by €0.007.
Is Novo Nordisk overvalued?
According to Wall Street analysts Novo Nordisk’s price is currently Undervalued.
Does Novo Nordisk pay dividends?
Novo Nordisk does not currently pay dividends.
What is Novo Nordisk’s EPS estimate?
Novo Nordisk’s EPS estimate is 0.82.
How many shares outstanding does Novo Nordisk have?
Novo Nordisk has 3,390,128,000 shares outstanding.
What happened to Novo Nordisk’s price movement after its last earnings report?
Novo Nordisk reported an EPS of €0.797 in its last earnings report, beating expectations of €0.79. Following the earnings report the stock price went down -4.444%.
Which hedge fund is a major shareholder of Novo Nordisk?
Currently, no hedge funds are holding shares in DE:NOVA
Novo Nordisk Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$56.49 (29.57% Upside)
$56.49 (29.57% Upside)
Blogger Sentiment
Bullish
DE:NOVA Sentiment 85%
Sector Average 70%
Sector Average 70%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-61.35%
12-Months-Change
Fundamentals
Return on Equity
75.95%
Trailing 12-Months
Asset Growth
42.90%
Trailing 12-Months
Company Description
Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
NOVA Company Deck
NOVA Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture of significant growth in overall sales and strategic advancements in R&D and capacity expansion, countered by a lowered full-year outlook and challenges in the U.S. and China markets. The positive sales and profit growth are overshadowed by the lowered expectations and ongoing challenges in the market.View all DE:NOVA earnings summariesNOVA Stock 12 Month Forecast
Average Price Target
€56.49
▲(29.57% Upside)
Technical Analysis
Ownership Overview
―
Insiders
1.39%
Mutual Funds
0.95% Other Institutional Investors
97.57% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---